Experimental RSV vax decreases severe infection in newborns, says Pfizer
The vaccine candidate is one of several shown to be safe and effective in phase III trials
An experimental maternal bivalent vaccine against respiratory syncytial virus appears to have high efficacy for preventing severe infection in early infancy, the manufacturer has announced.
Results from Pfizer’s large phase III trial also suggest the respiratory syncytial virus (RSV) vaccine — administered to pregnant women in the late second or third trimester — is well-tolerated in mothers and infants alike.
